Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis of the NCIC CTG BR.21 and SATURN trials

BACKGROUND: The clinical benefit of erlotinib in treating epidermal growth factor receptor (EGFR) wildtype non-small cell lung cancer (NSCLC) has been questioned. We examined the impact of erlotinib in confirmed EGFR wildtype patients in two placebo-controlled phase III trials: the National Cancer I...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Transl Lung Cancer Res
Main Authors: Osarogiagbon, Raymond U., Cappuzzo, Federico, Ciuleanu, Tudor, Leon, Larry, Klughammer, Barbara
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2015
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4549481/
https://ncbi.nlm.nih.gov/pubmed/26380188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2015.07.17
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki